Literature DB >> 27400930

Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.

Albert M Anderson1, Jeffrey L Lennox2, Mark M Mulligan2, David W Loring3, Henrik Zetterberg4,5, Kaj Blennow4, Cari Kessing6, Rajeth Koneru3, Kirk Easley7, William R Tyor3,8.   

Abstract

HIV-associated neurocognitive disorders (HANDs) continue to be common and are associated with increased morbidity and mortality. However, the underlying mechanisms in the combination antiretroviral therapy (cART) era are not fully understood. Interferon alpha (IFNα) is an antiviral cytokine found to be elevated in the cerebrospinal fluid (CSF) of individuals with advanced HIV-associated dementia in the pre-cART era. In this cross-sectional study, we investigated the association between IFNα and neurocognitive performance in ambulatory HIV-infected individuals with milder impairment. An eight-test neuropsychological battery representing six cognitive domains was administered. Individual scores were adjusted for demographic characteristics, and a composite neuropsychological score (NPT-8) was calculated. IFNα and CSF neurofilament light chain (NFL) levels were measured using enzyme-linked immunosorbent assay (ELISA). There were 15 chronically infected participants with a history of significant immunocompromise (median nadir CD4+ of 49 cells/μl). Most participants were neurocognitively impaired (mean global deficit score of 0.86). CSF IFNα negatively correlated with three individual tests (Trailmaking A, Trailmaking B, and Stroop Color-Word) as well as the composite NPT-8 score (r = -0.67, p = 0.006). These negative correlations persisted in multivariable analyses adjusting for chronic hepatitis B and C. Additionally, CSF IFNα correlated strongly with CSF NFL, a marker of neuronal damage (rho = 0.748, p = 0.0013). These results extend findings from individuals with severe HIV-associated dementia in the pre-cART era and suggest that IFNα may continue to play a role in HAND pathogenesis during the cART era. Further investigation into the role of IFNα is indicated.

Entities:  

Keywords:  Aids; HIV; Interferon alpha; Memory disorders

Mesh:

Substances:

Year:  2016        PMID: 27400930      PMCID: PMC5226942          DOI: 10.1007/s13365-016-0466-z

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  24 in total

1.  The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse model.

Authors:  Cari Fritz-French; Ramzi Shawahna; Jennifer E Ward; Leonard E Maroun; William R Tyor
Journal:  J Interferon Cytokine Res       Date:  2014-02-24       Impact factor: 2.607

Review 2.  Neurocognitive assessment in the diagnosis of HIV-associated neurocognitive disorders.

Authors:  Kevin Robertson; Sarah Yosief
Journal:  Semin Neurol       Date:  2014-04-08       Impact factor: 3.420

Review 3.  Interferon-α (IFNα) neurotoxicity.

Authors:  Cari Fritz-French; William Tyor
Journal:  Cytokine Growth Factor Rev       Date:  2012-02-17       Impact factor: 7.638

4.  CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival.

Authors:  Tobias Skillbäck; Bahman Farahmand; Jonathan W Bartlett; Christoffer Rosén; Niklas Mattsson; Katarina Nägga; Lena Kilander; Dorota Religa; Anders Wimo; Bengt Winblad; Lars Rosengren; Jonathan M Schott; Kaj Blennow; Maria Eriksdotter; Henrik Zetterberg
Journal:  Neurology       Date:  2014-10-22       Impact factor: 9.910

5.  The prevalence and incidence of neurocognitive impairment in the HAART era.

Authors:  Kevin R Robertson; Marlene Smurzynski; Thomas D Parsons; Kunling Wu; Ronald J Bosch; Julia Wu; Justin C McArthur; Ann C Collier; Scott R Evans; Ron J Ellis
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

6.  Assessment of an immunoassay for interferon-alpha in cerebrospinal fluid as a diagnostic aid in infections of the central nervous system.

Authors:  R J Abbott; I Bolderson; P J Gruer
Journal:  J Infect       Date:  1987-09       Impact factor: 6.072

7.  Serum levels of alpha-interferon and gamma-interferon in patients with acute and chronic viral hepatitis.

Authors:  S Kakumu; A Fuji; K Yoshioka; H Tahara
Journal:  Hepatogastroenterology       Date:  1989-04

8.  A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals.

Authors:  Thomas D Marcotte; Reena Deutsch; Benedict Daniel Michael; Donald Franklin; Debra Rosario Cookson; Ajay R Bharti; Igor Grant; Scott L Letendre
Journal:  J Neuroimmune Pharmacol       Date:  2013-10-08       Impact factor: 4.147

9.  Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers.

Authors:  Gareth A D Hardy; Scott Sieg; Benigno Rodriguez; Donald Anthony; Robert Asaad; Wei Jiang; Joseph Mudd; Timothy Schacker; Nicholas T Funderburg; Heather A Pilch-Cooper; Robert Debernardo; Ronald L Rabin; Michael M Lederman; Clifford V Harding
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

10.  APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.

Authors:  Lucette A Cysique; Timothy Hewitt; Juliana Croitoru-Lamoury; Kevin Taddei; Ralph N Martins; Constance S N Chew; Nicholas N W S Davies; Patricia Price; Bruce J Brew
Journal:  BMC Neurol       Date:  2015-04-01       Impact factor: 2.474

View more
  13 in total

1.  Imiquimod and interferon-alpha augment monocyte-mediated astrocyte secretion of MCP-1, IL-6 and IP-10 in a human co-culture system.

Authors:  Michael D Rizzo; Robert B Crawford; Anthony Bach; Sera Sermet; Andrea Amalfitano; Norbert E Kaminski
Journal:  J Neuroimmunol       Date:  2019-05-20       Impact factor: 3.478

Review 2.  Type I Interferons in NeuroHIV.

Authors:  Victoria E Thaney; Marcus Kaul
Journal:  Viral Immunol       Date:  2018-09-27       Impact factor: 2.257

Review 3.  Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder.

Authors:  Michael D Rizzo; Joseph E Henriquez; Lance K Blevins; Anthony Bach; Robert B Crawford; Norbert E Kaminski
Journal:  J Neuroimmune Pharmacol       Date:  2020-05-14       Impact factor: 4.147

4.  Aging, comorbidities, and the importance of finding biomarkers for HIV-associated neurocognitive disorders.

Authors:  Jacqueline Rosenthal; William Tyor
Journal:  J Neurovirol       Date:  2019-03-13       Impact factor: 2.643

5.  Heme oxygenase-1 promoter region (GT)n polymorphism associates with increased neuroimmune activation and risk for encephalitis in HIV infection.

Authors:  Alexander J Gill; Rolando Garza; Surendra S Ambegaokar; Benjamin B Gelman; Dennis L Kolson
Journal:  J Neuroinflammation       Date:  2018-03-06       Impact factor: 8.322

Review 6.  Optimal treatment of HIV-associated neurocognitive disorders: myths and reality. A critical review.

Authors:  Anastasia Bougea; Nikolaos Spantideas; Petros Galanis; George Gkekas; Thomas Thomaides
Journal:  Ther Adv Infect Dis       Date:  2019-04-04

7.  Linked CSF reduction of phosphorylated tau and IL-8 in HIV associated neurocognitive disorder.

Authors:  Tugba Ozturk; Alexander Kollhoff; Albert M Anderson; J Christina Howell; David W Loring; Drenna Waldrop-Valverde; Donald Franklin; Scott Letendre; William R Tyor; William T Hu
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

8.  Systemic and intrathecal immune activation in association with cerebral and cognitive outcomes in paediatric HIV.

Authors:  C Blokhuis; C F W Peeters; S Cohen; H J Scherpbier; T W Kuijpers; P Reiss; N A Kootstra; C E Teunissen; D Pajkrt
Journal:  Sci Rep       Date:  2019-05-29       Impact factor: 4.379

9.  Distinct cellular immune properties in cerebrospinal fluid are associated with cognition in HIV-infected individuals initiating antiretroviral therapy.

Authors:  Beret Amundson; Lillin Lai; Mark J Mulligan; Yong Xu; Zidou Zheng; Suprateek Kundu; Jeffrey L Lennox; Drenna Waldrop-Valverde; Donald Franklin; Alison Swaims-Kohlmeier; Scott L Letendre; Albert M Anderson
Journal:  J Neuroimmunol       Date:  2020-04-27       Impact factor: 3.478

Review 10.  Potential pharmacological approaches for the treatment of HIV-1 associated neurocognitive disorders.

Authors:  Amila Omeragic; Olanre Kayode; Md Tozammel Hoque; Reina Bendayan
Journal:  Fluids Barriers CNS       Date:  2020-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.